Note for mobile users: This table is best viewed in horizontal (landscape) orientation.

Investment Theses

Core strategy and high-conviction rationales for active positions

Ticker	Company	Reason I'm Buying
VKTX	Viking Therapeutics	The Macro Momentum: Viking operates in the massive Obesity / GLP-1 TAM, providing crucial portfolio diversification away from micro-cap binary and niche gene-therapy bets. They boast a heavily de-risked oral and subcutaneous GLP-1/GIP dual agonist pipeline that rivals Eli Lilly and Novo Nordisk. The Near-Term Catalyst (Q3 2026): The immediate price driver is Phase 1 maintenance data reading out in Q3. The trial tests if patients can maintain weight loss after a 19-week subcutaneous run by transitioning to a weekly or daily oral pill. Solving the long-term adherence and tolerability bottleneck via an oral maintenance pill is the holy grail for the space. Phase 3 Oral Initiation (Q4 2026): VKTX plans to initiate pivotal Phase 3 trials for their oral tablet in Q4, validating their stunning Phase 2 oral data (12.2% weight loss in just 13 weeks) and locking in their competitive timeline. The Capitalization & M&A: VKTX is exceptionally well-capitalized with roughly $600M+ in cash. While they filed an ATM to fund their massive ongoing Phase 3 subcutaneous trials (VANQUISH 1 & 2), the sheer size of the TAM and the constant hum of buyout speculation give it explosive upward mobility on any good data.
CTMX	CytomX Therapeutics	The Catalyst Torque: CTMX is a pure near-term catalyst play centered on a Q4 2026 (likely October) 40-patient dose-optimization update for Varseta-M, a first-in-class EpCAM ADC. Efficacy vs. Tolerability: Phase 1 data already proved the drug works, showing a 28% confirmed response rate in unselected late-line mCRC (compared to single-digit standard of care). However, high doses caused severe diarrhea. The October data must prove they have found the "Goldilocks" dose that maintains efficacy while resolving the tolerability limits. The Financial Floor: Trading around $4/share, the stock is heavily cushioned by ~$367M in pro forma cash (following a recent Regeneron payment), extending the runway deep into 2H 2028. The financing overhang is completely cleared into the data. The Platform Re-Rate: If the October data is clean, it not only locks in the H1 2027 registrational trial design but validates CytomX's entire "Probody" masking technology. Proving the platform works safely instantly makes them a high-value M&A target in an ADC-hungry market.
GLSI	Greenwich LifeSciences	The M&A Binary: The thesis has formally shifted from a clinical data hold to a near-term corporate acquisition or major partnership play. Management's changing language around the seriousness of suitor discussions points to an active M&A process. If a deal is struck, the asymmetry is massive — potentially a 3x to 7x return from current ~$16/share levels. The Lock-Up Signal: The timeline indicator has been driven by shifting lock-up periods for directors and early investors, with the latest extension anchoring insiders to January 2027. This signals the structural window in which management expects value to be unlocked. The Clinical Foundation: The underlying asset driving the buyout interest is GLSI-100, currently in the FLAMINGO-01 Phase 3 trial for breast cancer recurrence. The Phase 2b data at MD Anderson showed an 80%+ reduction in recurrences over 5 years. Insider conviction remains high, backed by significant and consistent CEO share purchases.
QURE	uniQure N.V.	The Regulatory Reversal: uniQure is developing AMT-130, a one-time gene therapy for Huntington's disease — a devastating, uniformly fatal neurodegenerative disorder with zero approved disease-modifying treatments. In June 2026, the FDA agreed at a Type B meeting that the 3-year Phase I/II data can serve as the primary basis for a BLA under accelerated approval. This was a dramatic reversal from March 2026, when the FDA had said the same data was insufficient. The Asymmetry: The stock traded around $70 in late 2025 on the strength of the 3-year data alone — before any regulatory validation, with the pathway uncertain. After the March rejection it collapsed, and even after June's positive reversal it trades in the mid-$40s. The market is pricing the company well below where it traded on the same data, but now with dramatically reduced regulatory risk. A simple round-trip to the pre-rejection price is a major move from here. The Catalyst Timeline: BLA submission is locked for Q3 2026, based on the now-accepted 3-year analysis. A separate 4-year data analysis arrives in the same quarter as additional supportive data, alongside a parallel UK MAA submission to the MHRA. BLA acceptance and Priority Review designation would follow into Q4 2026 / Q1 2027, with a potential accelerated approval decision in mid-2027. The Balance Sheet: With a large cash position following the June 2026 raise and runway well past the approval decision, the dilution risk that typically haunts pre-approval biotech is off the table. The capital needed to reach approval is already in hand. Pipeline Optionality: Beyond Huntington's, uniQure is advancing AMT-260 for refractory mesial temporal lobe epilepsy (early Cohort 1 data already positive) and AMT-191 for Fabry disease, providing additional shots on goal beyond the lead program.
CABA	Cabaletta Bio, Inc.	The Forever Low: Cabaletta is developing rese-cel (CABA-201), a CD19 CAR-T for autoimmune disease, and the stock trades near the $2.90 level where a blue-chip institutional syndicate — Bain Capital Life Sciences, Adage, Cormorant, and Eli Lilly — just bought $150M worth in May 2026. Buying here means buying alongside sophisticated money and a major pharma at essentially the same price, at the low end of the 52-week range, in a company funded into mid-2027. The Mechanism Edge: Rese-cel doesn't just suppress the immune system — it depletes the autoreactive B-cell compartment and lets the body repopulate with naive B cells that don't carry the autoimmune memory. It's a one-time depletion-and-reset rather than a standing therapy. The early preconditioning-free data (RESET-PV) suggests the reset can happen without harsh chemo lymphodepletion, which would open a far larger addressable population. The Data: Across the RESET program (myositis, SLE, systemic sclerosis, MG), the pattern has been consistent — patients who would have met the registrational primary endpoint did, with durability holding and a manageable safety profile. In the myositis Phase 1/2, roughly 83% of patients would have met the registrational endpoint, with durability out to 1.5 years. RMAT designation is in place. The Catalyst Path: The near-term drivers are the preconditioning-free durability data and higher-dose data in 2H 2026, plus initiation of the SSc registrational program in Q4 2026. The defining binary is the RESET-Myositis DM/ASyS registrational topline in mid-2027, which enables a myositis BLA in 2H 2027 (with potential priority review voucher eligibility via the juvenile cohort). The Thesis: This is my highest-conviction "structural low" entry. If the mid-2027 registrational data lands, I see a path to a 4x from here over 12–15 months — with the 2H 2026 catalysts converting the story and the anticipatory run-up starting before the readout. The Risk: The company will likely need to raise before the mid-2027 data. Given the annual cadence and accelerating burn, expect a raise around late 2026 / Q1 2027 — ideally into strength, as the May round was. If the run-up hasn't started when they need cash, a raise into weakness would reprice the floor lower.
HELP	Helus Pharma (Cybin)	The Mispriced Coin: HELP is developing HLP003, a deuterated psilocin analog for major depressive disorder, and the market is pricing in failure — the stock trades near cash value with a Q4 2026 Phase 3 topline (APPROACH) directly ahead. That combination, market skepticism plus a near-term binary, is exactly the asymmetric setup I look for: if the data hits, the re-rate is violent precisely because expectations are on the floor. The Read-Through I Trust: The single biggest reason for conviction is DFTX. MindMed's EMERGE Phase 3 in MDD just hit cleanly in June 2026 — 8.1-point placebo-adjusted MADRS, durable through week 12 — clearing the exact risks the market fears for psychedelic depression trials (functional unblinding, high placebo response, Phase 2-to-3 translation). The class just proved it can work in a powered Phase 3, and I own the name that proved it. The Data & Design: HLP003's Phase 2 showed a large, durable effect — a ~23-point MADRS reduction sustained at 12 months off just two doses, with response and remission rates climbing toward 100% and 71% at the 12-month mark. The deuteration engineers a predictable ~4-hour experience, addressing the practical duration knock on the class. Breakthrough Therapy Designation is in place, signaling the FDA sees substantial improvement over available therapy. The Catalyst Path: APPROACH Phase 3 topline is expected Q4 2026, with an FDA alignment goal on the approvable development program by year-end, and the complementary EMBRACE Phase 3 running in parallel to build the filing package. The Thesis: A high-probability Phase 3 (by my read, better than the market's implied odds) in a space I understand cold from DFTX, at a price that assumes it fails. If it hits, I see a path to roughly a 3x from here as the market re-rates from failure-priced to approvable-asset. The Risk: This is a single-asset binary — a miss on unblinding-adjusted numbers would be severe, and it's correlated to my DFTX psychedelic exposure, so a class-wide setback hits both together. Sized as a high-conviction bet I can absorb being wrong on, not as a settled outcome.
VLTLF	LibertyStream Infrastructure	From Concept to Producer: LibertyStream (formerly Volt Lithium) has officially transitioned from a speculative technology play to an active producer, successfully delivering their first tonne of finished lithium carbonate. They are now actively producing onsite with their partner, Select, effectively proving the commercial viability of extracting lithium from oil field brine. The Cost & Scale Advantage: While nearest competitors require massive capital injections (~$1.5B) and years of infrastructure layout to build a prototype, VLTLF's modular, highly capital-efficient model allows them to produce and scale rapidly from a tiny fraction of the cost. Strategic Domestic Supply: By turning oil field waste into a high-value commodity, they create an attractive secondary income stream for operators while serving as a highly secure, domestic supply of lithium for the US battery pipeline. Near-Term Catalysts: With production successfully de-risked, focus shifts to upcoming off-take agreements, additional JV announcements with major oil producers, the 1,000-tonne facility commissioning targeted for late 2026, and the planned uplisting to the NASDAQ.
MDNAF	Medicenna Therapeutics Inc.	The IL-2 Space Background: Some background is important here. Pharma poured many billions into IL-2 because of the promise of stimulating the body's own natural immune response to fight cancer, but toxicity levels were always too high. It has taken many years for the IL-2 space to re-emerge thanks to engineered versions like MDNA11. MDNA11 Mechanism Edge: MDNA11 selectively activates the "gas pedal" of the immune system (CD8+/NK cells) while removing the "brake" (Tregs) and the "danger" (Vascular Leak Syndrome). It's in Phase 1/2 across multiple cancer types, both as a monotherapy and in combination with Keytruda. The Clinical Picture: It is still early, but monotherapy results have been excellent. Recent combination data with Keytruda is showing real promise — Keytruda essentially shows the immune system which cells are the cancer cells, and MDNA11 amplifies the response. The Buyout Case: This is an excellent candidate for large pharma to acquire. Recent deals and acquisitions in the engineered IL-2 space are in the $1-2B range. So far, MDNA11 is proving it is best-in-class against the rest of the field. There are other drugs in the pipeline, but MDNA11 is the one to watch. The Risk: The company is dangerously low on funds. If no partnership or buyout is announced soon, expect further dilution that compresses per-share takeout math.
IMMX	Immix Biopharma Inc.	Market Monopoly: $IMMX is on track to deliver the first FDA-approved CAR-T for relapsed/refractory AL Amyloidosis—a "blue ocean" market with no current approved therapies and a potential $3B+ opportunity. Best-in-Class Efficacy: Recent Phase 2 data (ASH 2025) showed a 75% Complete Response (CR) rate, which is projected to reach 95% based on current bone marrow markers. This dwarfs the <10% response rates of current salvage therapies. The "Outpatient" Advantage: Unlike existing CAR-Ts that require intensive hospital stays, $IMMX's lead asset (NXC-201) has shown zero neurotoxicity and ultra-short (1-day) side effects. This allows for outpatient administration, making it cheaper for insurers and more accessible to the 95% of hospitals that can't currently handle "toxic" cell therapies. Near-Term Catalyst: The 40-patient BLA-enabling NEXICART-2 topline is expected September 2026, with a BLA submission to follow in 2H 2026. With a cash runway into 2027 and a clear regulatory path (RMAT designation), the approval is the primary value-unlock. Autoimmune Optionality: If the safety profile holds, NXC-201 is the perfect candidate to pivot into massive markets like Lupus or Myasthenia Gravis, where safety is the #1 barrier to entry.
CNVIF	Conavi Medical Corp.	CNVIF is a "disruptive med-tech" play on the only imaging system capable of combining the two gold standards of coronary diagnostics into a single device. The "Hybrid" Monopoly: Conavi's Novasight Hybrid System is the first and only platform to combine IVUS (ultrasound) and OCT (optical imaging) on a single catheter. This gives cardiologists a "super-view" of arteries that neither technology can provide alone. Imminent FDA Catalyst: In September 2025, the company submitted its next-generation system for FDA 510(k) clearance. A formal U.S. commercial launch is anticipated for 2H 2026, which serves as the primary near-term price driver. Guideline Tailwinds: Global medical guidelines (ACC/AHA/ESC) recently upgraded intravascular imaging to a Class 1A recommendation (the highest level). This mandate is forcing hospitals to adopt new imaging tech, creating a massive organic growth wave for $CNVIF. Freshly Capitalized: Following a $20M institutional raise in 2025 and an ongoing January 2026 public offering, the company has significantly de-risked its balance sheet to fund the upcoming U.S. sales force and manufacturing scale-up. Rapid Revenue Growth: Revenue grew from $2.2M to $9.1M in the last fiscal year (+300%). Analysts project revenue to continue growing at over 50% annually as the U.S. launch commences. UPDATE: Company announced FDA clearance as expected! I believe this is an excellent buy out candidate now. Most likely between now and end of 2026 at the latest.
LUCD	Lucid Diagnostics	The investment thesis for Lucid Diagnostics (LUCD) in 2026 centers on its transition from a clinical-stage diagnostic company to a commercially scalable oncology platform, primarily through its EsoGuard DNA test for the early detection of esophageal precancer. The bull case is anchored by recent major commercial wins, including a January 2026 U.S. Department of Veterans Affairs (VA) contract that grants access to nine million veterans, and a late-2025 unanimous expert consensus from the MolDx Contractor Advisory Committee supporting Medicare coverage. These catalysts address the company's historical "reimbursement gap," where high test volumes were previously unmatched by cash collections. With a strengthened balance sheet following a late-2025 public offering—extending the cash runway through late 2026—the thesis hinges on Lucid's ability to convert its $35 million+ revenue backlog into realized cash and scale toward an estimated break-even point of 6,000 tests per quarter. While the stock remains a high-risk, micro-cap play with significant cash burn, the imminent finalization of a national Medicare Local Coverage Determination (LCD) represents a binary "inflection point" that could re-rate the company from a speculative venture to a high-growth medical technology leader.
DFTX	Definium Therapeutics (formerly MindMed)	DFTX is a high-conviction, major binary play dominating the emerging neuropsychiatric medicine landscape. The core thesis rests on their lead asset, DT120 (formerly MM120), which is navigating the final stretches of Phase 3 testing for both Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The foundational EMERGE Phase 3 in MDD hit cleanly in June 2026 (8.1-point placebo-adjusted MADRS improvement, durable through week 12), de-risking the entire program since the same molecule underlies all the readouts. The near-term catalyst timeline is exceptionally tight: the Voyage GAD Phase 3 topline successfully read out in August 2026, followed by Panorama (GAD) in September 2026. With EMERGE positive and Voyage hitting its endpoints, DFTX has a clear line of sight to a Q1 2027 NDA submission, positioning them as an undisputed first-mover in a massive, largely unaddressed market. This is a classic high-impact binary asset where the clinical hits unlock multi-bagger potential.
TSHA	Taysha Gene Therapies	TSHA represents a highly asymmetric gene therapy play focused on TSHA-102 for Rett Syndrome, a devastating neurodevelopmental disorder with an enormous commercial vacuum. The thesis hinges on eliminating typical development timelines via accelerated regulatory pathways. Crucial validation arrived in June 2026 with the REVEAL Part A 12-month data confirming the historical 100% response rate is holding and deepening (milestone gains up +94% from the 6-month mark). With enrollment risk neutralized following completion of Pivotal dosing (overenrolled to N=17) in June 2026, the primary value inflection point is the 6-month Pivotal interim analysis, now expected 1H 2027 (pushed from H2 2026 by the overenrollment). The company is well-capitalized following its June 2026 raise, funding the run toward a mid-2027 BLA submission after an early-2027 FDA meeting.

Watchlist: Former Holdings

Positions previously held — theses retained for potential re-entry as catalysts approach

Ticker	Company	Thesis (Retained for Re-Entry)
KYTX	Kyverna Therapeutics, Inc.	KYTX is a "first-mover" play on the transition of CAR-T therapy from oncology into massive autoimmune markets, specifically targeting neuroimmunology. Pivotal Success in SPS: Kyverna reported positive Phase 2 registrational data for its lead asset, miv-cel (KYV-101), in Stiff Person Syndrome (SPS). The trial met its primary endpoint with a 46% median improvement in mobility, significantly exceeding the 20% clinical benchmark. The "Safety Shield": Miv-cel is designed to be safer than oncology CAR-Ts. Across all indications (SPS, MG, Lupus), it has shown zero high-grade ICANS and manageable CRS — essential for treating non-cancer patients. Balance Sheet Cushion: Roughly half the market cap is cash (runway into 2028), which provides real downside protection while awaiting the regulatory catalysts. Re-Entry Signal: The Q4 2026 SPS BLA completion and the Q1/Q2 2027 potential approval — which would be the first-ever FDA-approved autoimmune CAR-T — are the markers worth watching for re-entry.
HROW	Harrow Inc.	The Underappreciation: Harrow is the fastest-growing ophthalmology company most investors haven't yet priced as such. The infrastructure, leadership, and operational execution are already in place to deliver outsized growth. The Growth Window: Quarter-over-quarter growth should outpace what the market is currently pricing in, and that growth rate should last for the next 6-8 quarters and beyond. What the Market Misses: The current price reflects a steady specialty ophthalmics company. The reality is a commercial inflection underway with multiple simultaneous catalysts driving toward management's $250M quarterly revenue target by end of 2027 — roughly a 3x expansion from where revenue runs today. Re-Entry Signal: The January 2027 OPUVIZ (Eylea biosimilar) launch and progression toward the Q4 2027 revenue milestone are the markers worth watching for a re-entry.
VSTM	Verastem Oncology	VSTM is a high-conviction targeted oncology thesis centered on breaking down difficult-to-treat RAS-pathway driven tumors using their lead combinations. Near-term validation begins with the Phase 1 expansion data for VS-7375, which stands to trigger the stock's first major fundamental re-rating by validating its utility in the high-value KRAS G12D mutation space. The broader clinical thesis is anchored by the RAMP 205 expansion data in pancreatic cancer (PDAC) alongside formal FDA registrational engagement. With clear visibility toward entering registrational Phase 2 trials by Q1 2027 and a definitive Phase 3 RAMP 301 clinical readout slated for mid-2027, Verastem presents a highly organized clinical sequence targeting heavily underserved solid tumor markets. Re-Entry Signal: The mid-2027 RAMP 301 Phase 3 topline is the key binary worth watching. The June 2026 NSCLC Fast Track and TARGET-D 101 data updates are interim signals on the way there.

Data current for active portfolio positions Updated August 2026